Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Dr Serena Lucotti, who has been awarded 'Italy Made Me' prize for her DPhil project.

Dr Serena Lucotti, a postdoctoral researcher in the Mechanisms of Metastasis research group, has been awarded an Italy Made Me prize for her DPhil project entitled: ‘Targeting prostanoid biosynthesis during metastasis: the therapeutic potential of aspirin and beyond’.

During her DPhil, Serena studied the effect of aspirin and other anti-platelet drugs on cancer metastasis, which led her to discover a novel platelet signalling pathway that supports tumour cell dissemination through the bloodstream. Her work identifies new targets and therapeutic opportunities for the prevention of metastasis in cancer patients.

Serena received her award from the Ambassador, Raffaele Trombetta, at a ceremony at the Italian Embassy on 4th September. 

The Italy Made Me award recognises UK-based Italian researchers who received part of their training in Italy. There are prizes for innovative research in three categories: Life Sciences, Physical and Engineering Sciences, Social Sciences and Humanities. It is coordinated by the Italian Embassy in London, in collaboration with Il Circolo, the “Association of Italian Scientists in the United Kingdom” (AISUK) and other Italian academic associations in the UK.

Similar stories

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.